Mexico: Can Two Patents For The Same Invention Be Obtained Under Mexican Patent Law?

Last Updated: 22 June 2018
Article by Sergio Olivares, Jr. and Mauricio Sámano

The Mexican IPL is clear on the fact that it is not possible to obtain two patents for the same invention. However, there are certain scenarios in which this situation could in fact occur. Sergio Olivares, Jr. and Mauricio Sámano explain the situation.

As we mentioned in a previous publication, one of the objections that most applicants who seek to protect their pharmaceutical, chemical, and biotechnological inventions in Mexico have been forced to deal with is a double patenting objection. A double patenting objection is raised when an Examiner considers that the matter claimed in a patent application is already covered by a previously granted patent, in order to avoid the issuance of more than one patent(s) for the same invention.

In this sense, it is important to clarify that the Mexican IPL does not have a specific provision that prohibits double patenting. However, the Mexican Institute of Industrial Property (hereinafter referred to as 'IMPI') applies the criteria applied by most patent systems, which is that two patents cannot be granted for the same invention. The basis for the criteria applied by the IMPI is that an applicant has no legitimate interest in the proceedings that lead to the granting of a second patent for the same subject matter if he already possesses one granted patent for said matter. Unlike US patent law, which expressly defines double patenting and specifically mentions that there are two different types of double patenting rejections ('same invention' type double patenting and 'non-statutory' type double patenting), the IPL does not expressly define double patenting. This can lead to a series of different interpretations with each Examiner giving their specific prohibitions, creating an inherent uncertainty around the double patenting issue.

Notwithstanding the above, it is also worth mentioning that, nowadays, there are certain considerations that Examiners apply when issuing a double patenting objection. Specifically, Examiners analyze the scope of the issued patent, as well as the scope of the matter that the applicant is pursuing in the subsequent patent application and verify whether there is an overlap in the scope of protection. In other words, if the issued patent protects a series of chemical compounds and the subsequent patent application claims a series of chemical compounds wherein some of these compounds fall within the scope of the compounds claimed in the senior case (issued patent), the Examiner will issue a double patenting objection.

Similarly, it is important to consider that a selection invention would be an exception to this criterion, namely, if the applicant demonstrates that a specific chemical compound that is sought to be protected in the patent application and which falls within the scope of the chemical compounds granted in the senior case, has a surprising and unexpected technical effect, which could not have been deduced from the senior case, or from any state of the art documents, it is very likely that the Examiner will not issue a double patenting objection. In this case, it is possible that the Examiner will request the respective experimental evidence that demonstrates said surprising and unexpected technical effect. Said experimental evidence could be presented as an annex to the response to an office action.

Specific case scenario

Considering the lack of specific definitions in the Mexican IPL and the lack of Examiners' guidelines on how to address a double patenting objection, this particular objection has been a subject of discussion in Mexican patent practice.

With respect to the above, we felt it was important to discuss a very unusual Patent Prosecution case in which two patents were granted for essentially the same invention. The scenario, in this case, was particularly unique since this invention was developed jointly by two companies which filed a US non-provisional application. Afterwards, each company filed its own PCT application which later entered their respective national phases in several countries, such as Mexico.

When the application that our firm was handling (hereinafter referred to as Document A) reached substantive examination, the Mexican Examiner cited as relevant prior art, for novelty purposes, a certain Mexican patent (hereinafter referred to as Document B) in the name of another company which had the same international filing date as that of our clients' patent application. The situation was even stranger when we realized that Document A and Document B claimed priority of the same provisional US application. Even more unusual, the description of Document A and Document B was identical.

The Examiner insisted that Document A lacked novelty in view of Document B, since both cases referred to exactly the same invention and Document B was filed before the Mexican PTO before Document A. Olivares argued against this objection by mentioning that Document B could not be cited as prior art for Document A because both documents had the same priority. For this reason, Document B did not have a better right than Document A and could not be cited as a prior art document even though it referred to the same invention that was sought to be protected in Document A.

Olivares' prevailed in this case because we managed to demonstrate that IMPI's interpretation of Article 17 of our domestic law was incorrect. Article 17 of our domestic law establishes the following:

"Article 17. The prior art on the filing date of the patent application or, where applicable, the recognized priority date, shall be used to determine whether an invention is new and involves an inventive step. Furthermore, in order to determine whether an invention is new, the prior art shall include all patent applications filed in Mexico prior to said date and still pending, even if the publication referred to in Article 52 of this Law occurs at a later date."

For clarity sake, Article 52 of our domestic law establishes the following:

"Article 52. The publication of the pending patent application shall take place as soon as possible following the expiration of a period of 18 months from the filing date of the application or, where applicable, from the date of recognized priority. At the request of the applicant, the application shall be published prior to the expiration of said period."

With respect to the above, it is important to point out that the nature of Article 17 is to determine that it is not possible to have two patents for the same invention. In this regard, Article 17 establishes that it is possible to cite as prior art documents (only for novelty purposes), applications that were filed in Mexico at an earlier time. Specifically, Article 17 mentions that in Mexico, it is possible to cite as prior art, an application filed in Mexico that has an earlier priority date even though said application was not published at the time the second application was filed. This was not the case in our clients' application because both Documents A and B shared the same priority date and even more, they had the same priority number. In this sense, the Examiner's interpretation of our domestic law was also incorrect because he based his objection on the fact that Document B was filed before IMPI at an earlier date than Document A and overlooked the fact that the date triggering the legal effects in Mexico is that of the priority date and not that of the filing date in Mexico. This is also explained in Article 40 of our domestic law which mentions the following:

"Article 40. Where a patent is sought after having been applied for in other countries, the filing date in the country of first filing may be recognized as the priority date, provided that filing in Mexico occurs within the periods specified by international treaties or, failing that, within 12 months of the application for a patent in the country of origin."

Therefore, in this very particular case, it was possible to have two patents for the same invention.

In the end, Olivares prevailed and the Mexican Institute of Industrial Property issued the notice of Allowance for Document A.


Mexican patent practice still faces several challenges to mature as a consolidated patent system. As previously mentioned, the main issues in Mexican patent practice are the lack of Examiner guidelines and the presence of many grey areas in our domestic patent law.

However, one advantage that we see is that both Examiners and their Supervisors are open to having telephone conversations or faceto- face interviews with patent agents and attorneys, which simplifies and expedites the prosecution of patent applications in Mexico. In our particular case, these interviews were essential for obtaining the grant of document A instead of facing a rejection which would have cost the client more money and delayed the issuance of their patent application.

Another great advantage of the Mexican patent system is that currently, IMPI has Patent Prosecution Highway (PPH) agreements with several other patent offices around the world, such as the USPTO, EPO, SIPO, KIPO, CIPO, JPO, among others. Requests for PPH examination are an attractive option for applicants that seek to protect their inventions in Mexico because it is possible to obtain a Notice of Allowance for a corresponding Mexican application approximately 2 to 3 months after the PPH request is filed.

Also, an additional recent amendment to our domestic law that was published on March 13, 2018 and which will become in force on April 27, 2018 contains several modifications for patents and designs. Among the most interesting changes is that the term of protection for designs has changed to a term of 5 years, with five possible renewal periods, that could last up to 25 years, instead of the previous one 15-year term. Another very interesting modification is that after being published, all patent, utility models and design applications will be open for public inspection. Previously, it was only possible to consult the file wrapper when the patent application issued.

We are confident that the above amendments to our domestic law along with the International treaties that are currently under negotiation (for example TPP and the Free Trade Agreement with the European Union) will help in continuing to shape our patent system into a more mature one.

Originally published by The Patent Lawyer.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Becerril Coca & Becerril
Becerril Coca & Becerril
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Practice Guides
by Mondaq Advice Centres
Relevancy Powered by MondaqAI
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Becerril Coca & Becerril
Becerril Coca & Becerril
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions